A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease

Autores
Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; Tarleton, Rick L.
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.
Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Padilla, Ángel Marcelo. University of Georgia; Estados Unidos
Fil: White, Brooke. University of Georgia; Estados Unidos
Fil: Wang, Wei. University of Georgia; Estados Unidos
Fil: Tarleton, Rick L.. University of Georgia; Estados Unidos
Materia
DORMANCY
CHAGAS
TREATMENT
CLARIFICATION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/141920

id CONICETDig_f5539bf8b1b4a07357ad999ff77693e7
oai_identifier_str oai:ri.conicet.gov.ar:11336/141920
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas diseaseBustamante, Juan ManuelSánchez Valdéz, Fernando JavierPadilla, Ángel MarceloWhite, BrookeWang, WeiTarleton, Rick L.DORMANCYCHAGASTREATMENTCLARIFICATIONhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; ArgentinaFil: Padilla, Ángel Marcelo. University of Georgia; Estados UnidosFil: White, Brooke. University of Georgia; Estados UnidosFil: Wang, Wei. University of Georgia; Estados UnidosFil: Tarleton, Rick L.. University of Georgia; Estados UnidosAmerican Association for the Advancement of Science2020-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/141920Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-121946-6242CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1126/scitranslmed.abb7656info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/scitranslmed.abb7656info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:45:15Zoai:ri.conicet.gov.ar:11336/141920instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:45:15.328CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
title A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
spellingShingle A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
Bustamante, Juan Manuel
DORMANCY
CHAGAS
TREATMENT
CLARIFICATION
title_short A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
title_full A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
title_fullStr A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
title_full_unstemmed A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
title_sort A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
dc.creator.none.fl_str_mv Bustamante, Juan Manuel
Sánchez Valdéz, Fernando Javier
Padilla, Ángel Marcelo
White, Brooke
Wang, Wei
Tarleton, Rick L.
author Bustamante, Juan Manuel
author_facet Bustamante, Juan Manuel
Sánchez Valdéz, Fernando Javier
Padilla, Ángel Marcelo
White, Brooke
Wang, Wei
Tarleton, Rick L.
author_role author
author2 Sánchez Valdéz, Fernando Javier
Padilla, Ángel Marcelo
White, Brooke
Wang, Wei
Tarleton, Rick L.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv DORMANCY
CHAGAS
TREATMENT
CLARIFICATION
topic DORMANCY
CHAGAS
TREATMENT
CLARIFICATION
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.
Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Padilla, Ángel Marcelo. University of Georgia; Estados Unidos
Fil: White, Brooke. University of Georgia; Estados Unidos
Fil: Wang, Wei. University of Georgia; Estados Unidos
Fil: Tarleton, Rick L.. University of Georgia; Estados Unidos
description A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.
publishDate 2020
dc.date.none.fl_str_mv 2020-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/141920
Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-12
1946-6242
CONICET Digital
CONICET
url http://hdl.handle.net/11336/141920
identifier_str_mv Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-12
1946-6242
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1126/scitranslmed.abb7656
info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/scitranslmed.abb7656
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Association for the Advancement of Science
publisher.none.fl_str_mv American Association for the Advancement of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614491949498368
score 13.070432